Astrazeneca PLC 6-K, filed Mar 21, 2025
Astrazeneca PLC (AZN)
6-K
2025-03-21
For: 2025-03-21
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on March 21, 2025.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AZN invests $2.5bn in Beijing R&D &
manufacturing
21 March 2025
AstraZeneca to invest $2.5 billion in new global strategic R&D
centre, biotech agreements and manufacturing in
Beijing
AstraZeneca is establishing a new global strategic R&D centre
in Beijing, its second in China and sixth worldwide
Investment includes biotech agreements with Harbour BioMed, Syneron
Bio and BioKangtai
AstraZeneca today announced an investment of $2.5 billion in
Beijing to establish its sixth global strategic R&D centre
together with major research and manufacturing agreements that will
further advance life sciences in China. This investment over the
next five years is part of a strategic partnership with the Beijing
Municipal Government and the Beijing Economic-Technological
Development Area Administrative Office and includes agreements with
three biotechs; Harbour BioMed, Syneron Bio, and BioKangtai, and
follows the recent Fibrogen announcement. AstraZeneca expects
its Beijing workforce to grow to 1,700 employees.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: This
$2.5 billion investment reflects our belief in the world-class life
sciences ecosystem in Beijing, the extensive opportunities that
exist for collaboration and access to talent, and our continued
commitment to China. Our sixth strategic R&D centre will
partner with the cutting-edge biology and AI science in Beijing and
be a critical part of our global efforts to bring innovative
medicines to patients worldwide.
The new global strategic R&D centre in Beijing, AstraZeneca's
second in China following the opening of the Shanghai R&D
centre, will advance early-stage research and clinical development
and will be enabled by a new state-of-the-art AI and data science
laboratory. The new R&D centre will be located near
leading biotechs, research hospitals, and the National Medical
Products Administration in the Beijing International Pharmaceutical
Innovation Park (BioPark).
AstraZeneca is also establishing new R&D collaborations in
Beijing. This includes a strategic partnership with the Beijing
Cancer Hospital in translational research, data science, and
clinical development. AstraZeneca is signing two collaboration and
licensing agreements; one with Harbour BioMed to discover
multi-specific antibodies, and one with Syneron Bio to develop
macro-cyclic peptides.
In addition, AstraZeneca is launching a new joint venture with
BioKangtai, to develop, manufacture, and commercialise innovative
vaccines for respiratory and other infectious diseases for patients
in China and around the world. This will be AstraZeneca's first and
only vaccine manufacturing facility in China, which will be located
in the Beijing BioPark.
To support the development of the Beijing innovation ecosystem,
Pascal Soriot, CEO AstraZeneca, has been invited to join the
Beijing International Business Leaders Advisory Council
(IBLAC).
Notes
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
21 March 2025
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|